Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02785445 · ClinicalTrials.gov registry record · NA

Healthy.io Method Comparison & User Performance Study

A NA study of Diabetes and Kidney Failure, sponsored by Healthy.io.

Completed
Registry status
NA
Development phase
425
Enrollment target
2
Study locations

NCT02785445: Completed NA study of Diabetes and Kidney Failure, sponsored by Healthy.io.

NCT02785445 is a NA study of Diabetes and Kidney Failure that has completed, run by Healthy.io. The registered enrollment target is 425 participants, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02785445, a NA study of Diabetes and Kidney Failure, has completed, sponsored by Healthy.io.

COMPLETED
Registry status
NA
Development phase
425 participants
Enrollment target
2
Study locations

Study Summary

The objectives of the Healthy.io Method Comparison and User Performance Study are: 1. To evaluate the performance of Dip.io Device in comparison to the ACON U500 Mission® U500 Urine Analyzer. 2. To evaluate the user performance of Dip.io Device under actual use conditions (home environment) based on a user questionnaire and rating scale.

Primary Outcome

The primary objective of the study is to evaluate the exact agreement and the ±1 color block match of the Dip.io compared to the predicate device, for each analyte concentration (block).

Interventions

  • DEVICE Dip.io Home Based Dipstick Analyzer
  • DEVICE ACON U500 Mission® U500 Urine Analyzer

Study Locations (2)

Georgia

  • Atlanta Center for Medical Research - Atlanta

New York

  • AccuMed Research Associates - Garden City

Trial Details

FieldValue
Enrollment Target 425 participants
Start Date 2015-10
Est. Completion 2017-09
Phase NA
Healthy.io

7 total trials

What the finished NCT02785445 record still lists

NCT02785445 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, below the 3,027-participant average among 338 other Diabetes trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Dip.io Home Based Dipstick Analyzer is the first listed.

NCT02785445 reports a single indexed study location in Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT02785445 about?

NCT02785445 is a clinical study titled "Healthy.io Method Comparison & User Performance Study". The objectives of the Healthy.io Method Comparison and User Performance Study are: 1. To evaluate the performance of Dip.io Device in comparison to the ACON U500 Mission® U500 Urine Analyzer. 2. To evaluate the user performance of Dip.io Device under actual use conditions (home environment) based o...

What is the current status of trial NCT02785445?

This trial is currently completed. It is a NA study. The enrollment target is 425 participants. The study started on 2015-10. Estimated completion is 2017-09.

What conditions does trial NCT02785445 study?

This clinical trial studies the following conditions: Diabetes, Kidney Failure, Urinary Tract Infection.

What interventions are being tested in trial NCT02785445?

The interventions under investigation include: Dip.io Home Based Dipstick Analyzer (DEVICE), ACON U500 Mission® U500 Urine Analyzer (DEVICE).

Who is sponsoring clinical trial NCT02785445?

This trial is sponsored by Healthy.io, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02785445 being conducted?

This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02785445's enrollment target sits among peer trials

425 81st of 338 higher than 257 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04265430 · 425 participants · Phase 4

    Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

  • NCT04278690 · 425 participants · NA

    Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit

  • NCT05340738 · 425 participants · NA

    AI-Based Fidelity Feedback to Enhance CBT

  • NCT06693687 · 425 participants · NA

    A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02785445, the US trial registry maintained by the National Library of Medicine. NCT02785445 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.